Mechanisms of adverse effects of anti-VEGF therapy for cancer.
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibGuidance molecules in lung cancerModes of resistance to anti-angiogenic therapyThe Role of RhoJ in Endothelial Cell Biology and Tumor PathologyProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesSelective use of sorafenib in the treatment of thyroid cancerPrognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibPharmacologic resistance in colorectal cancer: a reviewThe Crossroads of Geriatric Cardiology and Cardio-OncologyRisk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsNanoemulsions in translational research-opportunities and challenges in targeted cancer therapyTargeting angiogenesis in squamous non-small cell lung cancerMicrovascular repair: post-angiogenesis vascular dynamicsPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisr84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionCancer and liver cirrhosis: implications on prognosis and managementAdaptation to antiangiogenic therapy in neurological tumorsQuercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cellsThe HILDA complex coordinates a conditional switch in the 3'-untranslated region of the VEGFA mRNAAnti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesisThe Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsA role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cellsIncreased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motilityMo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesisIncreased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Cancer drug related cardiotoxicity during breast cancer treatment.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.Angiogenic inhibition in high-grade gliomas: past, present and future.Designing a broad-spectrum integrative approach for cancer prevention and treatment.Circulating tumor cell data: integration with imaging and serum tumor markers for metastatic breast cancer patient management.Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.Ponatinib reduces viability, migration, and functionality of human endothelial cells.Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
P2860
Q21261282-BC1A3C12-7671-4771-ABBA-E5331ADA93CEQ24598659-BCAD7AA9-2CF0-4F3C-89B7-FA0F5813C57FQ24608005-AD1927DE-F5A8-453B-B24D-DBA10523303AQ26739169-7D454585-7865-4337-B3F0-164D900AE34AQ26751280-69195507-630E-4266-944F-4A692F9EF220Q26752891-E935F2D5-588E-4AB1-8236-A33C728534DBQ26765210-06649374-475F-4EF0-AB24-21C13CA566C0Q26769850-7D6204D3-156F-4095-ACD1-3B00D9CB17C5Q26778666-C2214C7C-5E93-484E-AA9E-7DB8D8722EC0Q26822790-09DA88F8-44B7-49ED-B483-ABF72C60545CQ26858849-4188C395-2104-4323-98B2-2E79FF33EC10Q26861341-B2B5A55C-DE8D-4087-9F84-03EAB09C76ADQ27004093-1BB6EA7D-E3AA-4730-8A04-CE0BDFBBEC2CQ27004170-F4ECB76E-E57C-48E8-9332-11AFE00ECED0Q27026453-8F4A7E56-C7D4-42A8-9D6B-DD5E0F50B587Q27321768-7949355C-A424-4C50-B07C-B91C25B3E924Q28068579-508C745B-C347-45BF-A337-17E29E61303CQ28082908-3B137181-11B4-426A-9890-2601C80DD495Q28480617-06E287B0-37E2-4A48-B8DB-6955E927E129Q28535448-A943640E-7294-4787-B276-49FAEAE0590DQ28535457-3B59D4B4-D659-4DC0-9318-4260B5F3E3F1Q28550616-4D5C17A1-1F53-4497-9393-A3E0D7B6ADF2Q28566820-A73301C4-1429-4D67-8B7F-F5B9B44D99DEQ28650438-2759824F-51BD-4F6C-B9D4-6FA4AEB353F7Q28820722-1A7467A1-DD3D-47EE-91BC-E66EDDCD5639Q28822397-C2DA7478-F5CC-4FA3-8183-48C4CE91C4D1Q30248296-FAB4B604-DFF8-4877-9C16-76579822A686Q30250303-3532D93A-83FF-4CE0-8C8B-8BE3848352B9Q30251498-09CF0B74-D1A6-452C-8F9D-14D8DC1D86CEQ30364937-44C9C0D2-56FD-439F-97FE-2D1420305ECFQ30453939-69C04714-5560-4121-B8B1-23E605D69909Q30455596-6690B790-A066-4500-8F0D-C78A86B253CEQ30736359-651695C2-D698-477F-B253-B2B61D6B1F67Q30815483-0F9D4C80-0BA8-475E-95FB-C78B4298A8F0Q33161260-347A6F48-72C2-498B-986A-52D461665649Q33364077-2BA6EFC3-21AD-4354-A1B2-BE1582C1E428Q33406359-54C4C07F-866F-4C5D-806B-FE8ADE78B29EQ33410375-01379594-2CB7-4874-B42A-4F1243D5E445Q33423350-62C5B961-752B-41B2-97EB-DF35026CAEBEQ33426343-4AD37091-40E3-447D-A261-A6463536A4EC
P2860
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@ast
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@en
type
label
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@ast
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@en
prefLabel
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@ast
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@en
P2860
P356
P1476
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603813
P407
P577
2007-05-22T00:00:00Z
2007-06-18T00:00:00Z